Personalized Treatment for Refractory H Pylori Infection

• Status: Recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

In this study, the investigators develop a personalized treatment according to culture-guided antibiotics plus high-dose proton-pump inhibitor and bismuth to treat refractory H pylori infection.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kaohsiung Veterans General Hospital.
• Collaborator: Kaohsiung Medical University Chung-Ho Memorial Hospital
• Treatments: Amoxicillin; Anti-Bacterial Agents; Antibiotics, Antitubercular; Bismuth; Bismuth tripotassium dicitrate; Clarithromycin; Levofloxacin; Ofloxacin; Rabeprazole; Tetracycline

Criteria

Inclusion Criteria:

H pylori-infected adult patients with at least two previous failed eradication attempts will be enrolled in this study after giving informed consent.

• positive results of both rapid urease test and histology,

• a positive result of Urea breath test,

• or a positive result of culture

Exclusion Criteria:

• ingestion of antibiotics, bismuth, or proton-pump inhibitor within the prior 4 weeks,

• patients with allergic history to the medications used,

• patients with previous gastric surgery,

• the coexistence of serious concomitant illness (for example, decompensated liver cirrhosis, uremia),

• pregnant women.